



**(301) 366-4960**

**(Issuer Telephone number)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Items.**

On January 27, 2016, Neuralstem, Inc. (the “Company”) announced that Dr. Karl Johe, Ph.D., the Company’s chief scientific officer and chairman provided an update on the Company’s ongoing NSI-566 cell therapy programs at the Phacilitate Cell & Gene Therapy World conference in Washington D.C. A copy of the press release and slides presented at the conference are attached to this report as Exhibits 99.01 and 99.02, respectively. Additionally, the slides from the presentation are also available on the Company's website at [www.neuralstem.com](http://www.neuralstem.com).

**Item 9.01 Financial Statement and Exhibits.**

**Exhibit**

<b>No.</b>	<b>Description</b>
99.01	Press Release Dated January 27, 2016
99.02	Slides presented at conference

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 27, 2016 Neuralstem, Inc.

/s/ Richard Garr  
By: Richard Garr  
Chief Executive Officer

**INDEX OF EXHIBITS**

**Exhibit**

<b>No.</b>	<b>Description</b>
99.01	Press Release Dated January 27, 2016
99.02	Slides presented at conference